BiotechTube

Ganaplacide + Itraconazole

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malaria

Conditions

Malaria

Trial Timeline

Nov 18, 2021 → May 14, 2022

NCT ID
NCT05084651

About Ganaplacide + Itraconazole

Ganaplacide + Itraconazole is a phase 1 stage product being developed by Novartis for Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT05084651. Target conditions include Malaria.

What happened to similar drugs?

11 of 19 similar drugs in Malaria were approved

Approved (11) Terminated (1) Active (8)
✅COA566NovartisApproved
✅Artesunate-mefloquine + Atovaquone-proguanil + Artemether-lumefantrineNovartisApproved
✅Co-artemetherNovartisApproved
✅Artemether-lumefantrineNovartisApproved
✅Flavoquine®, Camoquin® Suspension + Flavoquine®, Camoquin® SuspensionPfizerApproved
✅Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination) + Coartem® (arthemether+ lumefantrine)SanofiApproved
✅Artesunate + Artesunate + Sulfadoxine-Pyrimethamine + arthemether + lumefantrineSanofiApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05084651Phase 1Completed

Competing Products

20 competing products in Malaria

See all competitors
ProductCompanyStageHype Score
SAR97276ASanofiPhase 2
27
SJ733 + CobicistatEisaiPhase 1
29
(+)-SJ000557733 (SJ733)EisaiPhase 2
35
E1018 + PlaceboEisaiPhase 1
36
ZY19489 + Ferroquine (FQ) + PlaceboZydus LifesciencesPhase 1
36
ZY19489 Capsule + Placebo CapsuleZydus LifesciencesPhase 1
29
M5717 330 mg + M5717 500 mg + M5717 660 mg + Pyronaridine 360 mg + Pyronaridine 360 mg + Pyronaridine 540 mg + Pyronaridine 720 mgMerckPhase 2
35
MK-7602 + Artemether/lumefantrine + Primaquine + Artesunate + Atovaquone/proguanilMerckPhase 1
29
M5717 60 mg + Pyronaridine + Atovaquone-Proguanil + M5717 200 mg + M5717 660mgMerckPhase 2
35
KLU156 + CoartemNovartisPhase 3
40
KAF156NovartisPhase 2
35
KAE609 + IV Artesunate + CoartemNovartisPhase 2
35
KAE609NovartisPhase 2
35
artemether:lumefantrine (2.5 mg:30 mg)NovartisPhase 2/3
30
Artemether-lumefantrine (COA566)NovartisPhase 2/3
38
INE963NovartisPhase 2
35
KAE609 + Piperaquine PhosphateNovartisPhase 1
21
Artemether-lumefantrineNovartisPhase 3
40
KAE609 + SoC (Coartem) + KLU156NovartisPhase 2
35
KAF156 + Coartem + Lumefantrine Solid Dispersion FormulationNovartisPhase 2
35